Oculis (NASDAQ:OCS) Price Target Lowered to $29.00 at HC Wainwright

Oculis (NASDAQ:OCS) had its price target cut by research analysts at HC Wainwright from $30.00 to $29.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 53.93% from the company’s previous close.

Separately, Chardan Capital restated a “buy” rating and set a $28.00 price target on shares of Oculis in a research note on Tuesday, January 7th.

Oculis Trading Up 2.4 %

Shares of OCS stock opened at $18.84 on Thursday. The firm has a 50-day moving average price of $20.82 and a 200 day moving average price of $16.86. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $763.10 million, a price-to-earnings ratio of -9.76 and a beta of 0.02. Oculis has a twelve month low of $10.55 and a twelve month high of $23.08.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. Research analysts forecast that Oculis will post -2.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

Large investors have recently modified their holdings of the stock. Bellevue Group AG bought a new stake in shares of Oculis in the 4th quarter valued at approximately $170,000. XTX Topco Ltd acquired a new stake in Oculis during the fourth quarter worth about $225,000. Geode Capital Management LLC boosted its stake in Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after acquiring an additional 1,800 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Oculis during the 4th quarter worth approximately $389,000. Finally, Bank of America Corp DE grew its stake in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after buying an additional 10,667 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.